MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock from...
$3,551K
(4338.75%↑ Y/Y)
Net cash provided by
financing activities
$3,551K
(4338.75%↑ Y/Y)
Net increase
(decrease) in cash and cash...
$1,577K
(101.07%↑ Y/Y)
Canceled cashflow
$1,974K
Accounts payable and
accrued expenses
$23,398K
(332.02%↑ Y/Y)
Stock-based compensation
$6,712K
(-51.40%↓ Y/Y)
Accrued interest on
revenue interest...
$3,998K
Other
-$1,283K
(59.02%↑ Y/Y)
Amortization of debt discount
$912K
(-36.22%↓ Y/Y)
Prepaid expenses and
other current assets
-$132K
(97.89%↑ Y/Y)
Depreciation and
amortization
$114K
(-67.34%↓ Y/Y)
Net cash used in
operating activities
-$1,930K
(98.69%↑ Y/Y)
Net cash used in
investing activities
-$44K
(61.74%↑ Y/Y)
Canceled cashflow
$36,549K
Net loss
-$17,582K
(89.67%↑ Y/Y)
Cash paid for
property and equipment
$44K
(-61.74%↓ Y/Y)
Accounts receivable, net
$16,697K
(34.03%↑ Y/Y)
Inventory
$3,956K
(-72.10%↓ Y/Y)
Accrued interest
-$239K
(-655.81%↓ Y/Y)
Operating right-of-use
assets and lease...
-$5K
(-107.58%↓ Y/Y)
Back
Back
Cash Flow
Phathom Pharmaceuticals, Inc. (PHAT)
Phathom Pharmaceuticals, Inc. (PHAT)
source: myfinsight.com